Gilead Sciences (NASDAQ:GILD) has received a positive recommendation for approval from European regulators for its drug ...

The EMA’s Committee for Medicinal Products for Human Use (CHMP) determined that expected clinical benefits of seladelpar include delayed development of liver fibrosis and cirrhosis, potentially ...

Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy, and ...

The Institute for Clinical and Economic Review flagged five drugs whose prices were raised in 2023 with no evidence to ...

The U.S. Food and Drug Administration in August granted accelerated approval to seladelpar, which the Foster City, Calif., company markets as Livdelzi. The drug was the key asset in Gilead's $4.3 ...

Gilead Sciences names Sanofi's Dietmar Berger as new CMO, replacing Merdad Parsey amid challenging year marked by setbacks ...

Berger specialized in cancer long before joining Genentech, holding oncology global clinical development roles at Amgen and ...

Results for the Marion Star Preseason Player of the Year Polls for boys and girls basketball and bowling are revealed here.

Civil Rights icon and Nashville native Vencen Horsley has died. Horsley participated in sit-ins and fought against ...

(RTTNews) - Gilead Sciences, Inc. (GILD) announced Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending ...

New research from Karolinska Institutet in Sweden highlights the possibility of screening people with type 2 diabetes for liver damage at the same time as they undergo screening for eye disease. The ...